<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01836172</url>
  </required_header>
  <id_info>
    <org_study_id>HW2012-YJP002</org_study_id>
    <nct_id>NCT01836172</nct_id>
  </id_info>
  <brief_title>YJP-14 Capsules for the Treatment of Endothelial Dysfunction in Patients With Diabetes Mellitus</brief_title>
  <official_title>Multicenter, Randomized, Double Blind, Placebo-controlled, Phase II Clinical Trial to Evaluate the Safety and Efficacy of YJP-14 Capsules for the Treatment of Endothelial Dysfunction in Patients With Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Han Wha Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Han Wha Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of YJP-14 capsules for the
      treatment of endothelial dysfunction in patients with diabetes mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary purpose of this study is to demonstrate superior effect of YJP-14 three doses,
      25, 50 and 100 mg t.i.d on endothelial dysfunction in diabetes mellitus indicated as mean
      change difference of flow-mediated dilation (FMD), compared to placebo group after treatment
      of 12 weeks.

      The secondary purposes of this study are divided into three as follows;

        -  Clinically significant effect of YJP-14 three doses, 25, 50 and 100 mg t.i.d on
           endothelial dysfunction in diabetes mellitus indicated as mean change difference of FMD,
           compared to placebo group after treatment of 8 weeks.

        -  Clinically significant effect of YJP-14 three doses, 25, 50 and 100 mg t.i.d on insulin
           resistance in diabetes mellitus indicated as mean change difference of Homeostasis Model
           Assessment-Insulin Resistance (HOMA-IR), compared to placebo group after treatment of 4,
           8 and 12 weeks.

        -  Clinically significant effect of YJP-14 three doses, 25, 50 and 100 mg t.i.d on mean
           change difference of blood pressure in diabetes mellitus, compared to placebo group
           after treatment of 4, 8 and 12 weeks.

      The exploratory purposes of this study are divided into two as follows;

        -  Clinically significant effect of YJP-14 three doses, 25, 50 and 100 mg t.i.d on blood
           glucose level in diabetes mellitus indicated as mean change difference of HbA1c,
           compared to placebo group after treatment of 12 weeks.

        -  Clinically significant effect of YJP-14 three doses, 25, 50 and 100 mg t.i.d on vascular
           stiffness in diabetes mellitus indicated as mean change difference of blood lipids (LDL,
           HDL and TG), compared to placebo group after treatment of 12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flow-mediated dilation (FMD)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Flow-mediated dilation (FMD) Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) Systolic and Diastolic Blood Pressure</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Homeostasis model assessment-insulin resistance (HOMA-IR)</measure>
    <time_frame>4, 8, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic and Diastolic Blood Pressure</measure>
    <time_frame>4, 8, 12 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>HbA1c Serum lipids (LDL, HDL and TG)</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Serum Lipids (LDL, HDL and TG)</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Diabetic Complication</condition>
  <arm_group>
    <arm_group_label>Placebo t.i.d.</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo t.i.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YJP-14 25 mg t.i.d.</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>YJP-14 25 mg t.i.d. YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YJP-14 50 mg t.i.d.</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>YJP-14 50 mg t.i.d. YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YJP-14 100 mg t.i.d.</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems. YJP-14 100 mg t.i.d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YJP-14</intervention_name>
    <description>An 50% ethanolic extract of Lindera obtusiloba stems</description>
    <arm_group_label>Placebo t.i.d.</arm_group_label>
    <arm_group_label>YJP-14 25 mg t.i.d.</arm_group_label>
    <arm_group_label>YJP-14 50 mg t.i.d.</arm_group_label>
    <arm_group_label>YJP-14 100 mg t.i.d.</arm_group_label>
    <other_name>An 50% ethanolic extract of Lindera obtusiloba stems</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Adult-onset DM (defined as fasting glucose greater than 125 mg/dl or by ongoing treatment
        with an oral hypoglycemic agent), Endothelial dysfunction: FMD below 6.7%, LDL cholesterol
        level less than 140 mg/dl, Patients agreed to Informed Consent Form

        Exclusion Criteria: (Key exclusion criteria) Uncontrolled arterial hypertension (above
        139/90 mmHg) or hypotension (below 80/50 mmHg), Severe diabetic complication: diabetic
        nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic vascular complications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Byung-Hee Oh, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Internal medicine, Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Lee JO, Oak MH, Jung SH, Park DH, Auger C, Kim KR, Lee SW, Schini-Kerth VB. An ethanolic extract of Lindera obtusiloba stems causes NO-mediated endothelium-dependent relaxations in rat aortic rings and prevents angiotensin II-induced hypertension and endothelial dysfunction in rats. Naunyn Schmiedebergs Arch Pharmacol. 2011 Jun;383(6):635-45. doi: 10.1007/s00210-011-0643-9. Epub 2011 May 2.</citation>
    <PMID>21533989</PMID>
  </reference>
  <reference>
    <citation>Lee JO, Auger C, Park DH, Kang M, Oak MH, Kim KR, Schini-Kerth VB. An ethanolic extract of Lindera obtusiloba stems, YJP-14, improves endothelial dysfunction, metabolic parameters and physical performance in diabetic db/db mice. PLoS One. 2013 Jun 3;8(6):e65227. doi: 10.1371/journal.pone.0065227. Print 2013.</citation>
    <PMID>23755196</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2013</study_first_submitted>
  <study_first_submitted_qc>April 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2013</study_first_posted>
  <last_update_submitted>August 16, 2016</last_update_submitted>
  <last_update_submitted_qc>August 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>The treatment of diabetic complication</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Complications</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

